Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.
Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.
Theratechnologies (NASDAQ: THTX) ha tenuto la sua assemblea annuale virtuale degli azionisti il 29 maggio 2025. Durante l'incontro, gli azionisti hanno eletto otto amministratori nel Consiglio di Amministrazione della Società per un mandato di un anno. Tutti i candidati proposti sono stati eletti con tassi di approvazione compresi tra 77,98% e 84,03%. Joseph Arena ha ottenuto il maggior sostegno degli azionisti con il 84,03% dei voti favorevoli, mentre Dawn Svoronos ha ricevuto il 77,98% dei voti a favore.
Inoltre, gli azionisti hanno nominato KPMG LLP come revisori contabili della Società per l'esercizio in corso e hanno approvato un piano omnicomprensivo di incentivi a lungo termine a beneficio degli amministratori, dirigenti e dipendenti della Società e delle sue controllate.
Theratechnologies (NASDAQ: THTX) celebró su junta anual virtual de accionistas el 29 de mayo de 2025. Durante la reunión, los accionistas eligieron a ocho directores para la Junta de la Compañía por un período de un año. Todos los candidatos propuestos fueron elegidos con tasas de aprobación que oscilaron entre 77,98% y 84,03%. Joseph Arena recibió el mayor apoyo de los accionistas con un 84,03% de votos a favor, mientras que Dawn Svoronos obtuvo un 77,98% de votos favorables.
Además, los accionistas nombraron a KPMG LLP como auditores de la Compañía para el año fiscal actual y aprobaron un plan integral de incentivos a largo plazo que beneficia a los directores, ejecutivos y empleados de la Compañía y sus subsidiarias.
Theratechnologies (NASDAQ: THTX)는 2025년 5월 29일 연례 가상 주주총회를 개최했습니다. 회의에서 주주들은 회사 이사회에 1년 임기의 8명의 이사를 선출했습니다. 제안된 모든 후보자가 77.98%에서 84.03% 사이의 승인율로 성공적으로 선출되었습니다. Joseph Arena가 84.03%의 찬성표로 가장 높은 주주 지지를 받았으며, Dawn Svoronos는 77.98%의 찬성표를 받았습니다.
또한, 주주들은 KPMG LLP를 올해 회계연도 회사 감사인으로 임명하고, 회사 및 자회사의 이사, 임원, 직원들을 위한 종합 장기 인센티브 계획을 승인했습니다.
Theratechnologies (NASDAQ : THTX) a tenu son assemblée annuelle virtuelle des actionnaires le 29 mai 2025. Lors de cette réunion, les actionnaires ont élu huit administrateurs au conseil d'administration de la société pour un mandat d'un an. Tous les candidats proposés ont été élus avec des taux d'approbation allant de 77,98 % à 84,03 %. Joseph Arena a obtenu le plus grand soutien des actionnaires avec 84,03 % des voix en sa faveur, tandis que Dawn Svoronos a reçu 77,98 % des votes favorables.
De plus, les actionnaires ont nommé KPMG LLP en tant que commissaires aux comptes de la société pour l'exercice en cours et ont approuvé un plan global d'incitation à long terme bénéficiant aux administrateurs, dirigeants et employés de la société et de ses filiales.
Theratechnologies (NASDAQ: THTX) hielt am 29. Mai 2025 seine jährliche virtuelle Hauptversammlung ab. Während der Versammlung wählten die Aktionäre acht Direktoren für den Vorstand des Unternehmens für eine einjährige Amtszeit. Alle vorgeschlagenen Kandidaten wurden mit Zustimmungsraten von 77,98 % bis 84,03 % erfolgreich gewählt. Joseph Arena erhielt mit 84,03 % die höchste Zustimmung der Aktionäre, während Dawn Svoronos 77,98 % der positiven Stimmen erhielt.
Zusätzlich bestellten die Aktionäre KPMG LLP als Wirtschaftsprüfer des Unternehmens für das laufende Geschäftsjahr und genehmigten einen umfassenden langfristigen Anreizplan zugunsten der Direktoren, Führungskräfte und Mitarbeiter des Unternehmens und seiner Tochtergesellschaften.
- None.
- None.
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.
All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |
| Joseph Arena | 20,473,944 | 3,890,222 | ||
| Frank Holler | 19,089,786 | 5,274,380 | ||
| Paul Lévesque | 19,027,772 | 5,336,394 | ||
| Andrew Molson | 19,066,145 | 5,298,021 | ||
| Dawn Svoronos | 18,998,230 | 5,365,936 | ||
| Elina Tea | 19,163,502 | 5,200,664 | ||
| Dale Weil | 19,005,768 | 5,358,398 | ||
| Jordan Zwick | 19,618,725 | 4,745,441 | ||
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
514-336-7800
FAQ
Who was elected to Theratechnologies (THTX) Board of Directors in 2025?
What was the highest approval rate for THTX board members in the 2025 election?
What additional matters were approved at Theratechnologies' 2025 annual meeting?
How was Theratechnologies' 2025 annual shareholder meeting conducted?
